TScan Therapeutics(US:TCRX) GlobeNewswire News Room·2025-08-12 11:00Core Insights - TScan Therapeutics, Inc. is focused on developing T cell receptor-engineered T cell therapies for cancer treatment, with significant updates on their clinical trials and financial performance [11] Financial Performance - Revenue for Q2 2025 was $3.1 million, a substantial increase from $0.5 million in Q2 2024, primarily due to research activities related to a collaboration with Amgen [5] - Research and development expenses for Q2 2025 were $32.6 million, up from $26.9 million in Q2 2024, driven by increased laboratory supplies and personnel costs [6] - General and administrative expenses for Q2 2025 were $9.1 million, compared to $7.8 million in Q2 2024, mainly due to higher personnel expenses [7] - The net loss for Q2 2025 was $37.0 million, compared to $31.7 million in Q2 2024, with net interest income of $1.7 million in 2025 and $2.5 million in 2024 [9] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $218.0 million, expected to fund operations into Q1 2027 [9] Clinical Development Updates - The company plans to dose its first solid tumor patients with multiplex TCR-T in Q3 2025 and share safety and preliminary response data in Q1 2026 [2][8] - TScan's lead TCR-T therapy candidate, TSC-101, is designed to treat residual disease in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation [3] - The ImmunoBank is being developed to provide multiple TCR-T therapy candidates targeting various cancer-associated antigens to address tumor heterogeneity [4] Upcoming Milestones - TScan plans to present two-year relapse data from the ALLOHA Phase 1 trial by the end of 2025 [8] - The company expects to initiate a registrational trial for TSC-101 in the second half of 2025, pending regulatory feedback [8] - An investigational new drug (IND) application for TSC-102-A0301 is anticipated to be filed in the second half of 2025 [8]